Company intelligence / Profile preview

Hunan Antai Kangcheng Biotechnology

Hunan, China

Ownership: Private
Development stage: Preclinical

Overview

The company’s TEFT device demonstrated robust anti-proliferative effects against glioblastoma cell lines and patient-derived cultures in vitro. In rat models, TEFT significantly reduced tumor volume and prolonged survival compared to controls. Efficacy was dependent on frequency, duration, field strength, and output mode—with random sequence output being most effective. No human clinical trial outcomes are published yet.

Therapeutic areas: OncologyNeurology
Modalities: Tumor electric field therapy devices/medical devices for cancer treatmentNeurorehabilitation technologiesNo direct evidence for small molecules or biologics as primary modalities
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

TEFT

Pre-clinical

Indications: Glioblastoma

Beyond the preview

Go deeper on Hunan Antai Kangcheng Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hunan Antai Kangcheng Biotechnology.

Explore the full profile